DEVELOPMENT OF FIRST-IN-CLASS ERAP2 INHIBITORS TO MODULATE THE CANCER IMMUNOPEPTIDOME

Our collaborator, GreyWolf Therapeutics, has uncovered the effect of aminopeptidase ERAP2 inhibition for generating the de novo antitumor T-cell responses, thereby overcoming the resistance mechanism for current immune-oncology therapy.

Learn more about leveraging our TrueDiscovery® immunopeptidomics CRO services to overcome the challenges in immune-oncology.

Disclaimer: The contact information provided for poster download will also be shared with GreyWolf Therapeutics